Grail Shares Plunge 47.7% After Cancer Screening Trial Failure
Grail Inc’s three-year cancer screening trial failed to meet its primary endpoint, triggering a 47.7% intraday share plunge to the lowest level since September. Daily options volume rose 41-fold, led by the February 60 calls as short interest of 14.5% of float intensifies bearish pressure.
1. Cancer Screening Trial Fails Primary Endpoint
Grail Inc’s three-year multi-cancer early detection study did not meet its primary accuracy and sensitivity targets, disappointing investors and raising concerns over the technology’s clinical viability.
2. Shares Drop 47.7% Intraday
Shares tumbled 47.7% intraday to a $53 level unseen since September, marking the largest single-day percentage drop since IPO and reversing earlier year-on-year gains.
3. Options Volume and Short Interest Surge
Options volume soared to 41 times the daily average, with February 60 calls most active, while short interest at 14.5% of float points to amplified bearish sentiment that could pressure the stock further.
4. Company Outlook and Next Steps
Management now faces pressure to reassess trial protocols, secure additional funding and clarify regulatory pathways as the company seeks to restore investor confidence and strategic direction.